Mast cell mediator release and TGF-β pathway

The Mast cell mediator release and TGF-β pathway refers to the integrated biological processes involving the activation of mast cells and the subsequent signaling cascade of Transforming Growth Factor-beta (TGF-β) (Source: PubMed, PMID: 11753360). Mast cells are immune cells that, upon stimulation, release a variety of pro-inflammatory mediators such as histamine, tryptase, and cytokines, which contribute to allergic reactions and chronic inflammation (Source: StatPearls, Mast Cell Activation Syndrome). The TGF-β pathway is a critical regulator of cell growth, differentiation, and the production of extracellular matrix components, often acting as a master regulator of fibrosis (Source: Nature Reviews Molecular Cell Biology, TGF-β signaling). In many pathological states, mast cell-derived mediators can activate or enhance TGF-β signaling, leading to a cycle of persistent inflammation and tissue scarring (Source: Journal of Allergy and Clinical Immunology). Pharmacological agents such as Tranilast are designed to modulate this axis by stabilizing mast cell membranes to prevent mediator release and by inhibiting TGF-β-induced SMAD signaling and collagen production (Source: PubChem, Tranilast). Targeting this dual process provides a therapeutic strategy to address both the acute inflammatory triggers and the chronic structural remodeling associated with these diseases.

Other names

Mast cell-TGF-beta axisTGF-beta signaling and mast cell activationMast cell degranulation and TGF-beta pathway

Inhibition of mast cell degranulation and suppression of TGF-beta-mediated signaling and collagen synthesis.